NXTC
NextCure, Inc.Healthcare·Biotechnology
$6.20
$17M market cap
Revenue
$0.0M
Free Cash Flow
$-21.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Le
2-Year Price History
$7.83-53.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -9.8 | -10.1 | -9.8 | -13.4 | -13.4 | -0.0 | 29.7 | 3.9 | 5.2 | -591.6% | -- | -- |
| Act | 2025-Q4 | 0.0 | -9.4 | -9.8 | -9.4 | -7.6 | -7.6 | -0.0 | 41.8 | 5.2 | 3.5 | -236.4% | -- | -- |
Valuation & Metrics
Market Stats
Price$6.20
Market Cap$17M
Enterprise Value$-9M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-126.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-19.2M
Free Cash Flow$-21.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-414.0%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.1M
Days to Cover1.0
Change (vs Prior)+0.2%
Need at least 2 settlement dates for chart
Employees
Headcount43
Revenue / Employee$0
Gross Profit / Employee$-6,581
Cash Runway
17.0months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
73.4%(+58.3% YoY)
22 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
8.9%(+6.4% YoY)
4 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
0 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Squadron Capital Management LLC | $2.8M | $13.82 | +$299K | +$2.8M | +18.4% | $250M |
| Affinity Asset Advisors, LLC | $2.6M | $7.73 | −$58K | +$2.6M | +0.5% | $1.60B |
| Ikarian Capital, LLC | $2.5M | $14.19 | +$0 | +$2.5M | -8.9% | $698M |
| Sofinnova Investments, Inc. | $2.4M | $5.86 | +$0 | +$2.4M | +2.6% | $1.94B |
| SILVERARC CAPITAL MANAGEMENT, LLC | $1.9M | $14.19 | +$0 | +$1.9M | -0.2% | $843M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.7M | $10.68 | +$1.7M | +$1.7M | — | $4.04T |
| PFIZER INC | $1.5M | $5.86 | −$46K | +$1.5M | +4.4% | $239M |
| Opaleye Management Inc. | $1.5M | $10.68 | +$1.5M | +$1.5M | +0.9% | $759M |
| AWM Investment Company, Inc. | $1.2M | $14.19 | +$0 | +$1.2M | -0.7% | $903M |
| Exome Asset Management LLC | $1.2M | $14.19 | −$529K | +$1.2M | +3.2% | $166M |
| BOOTHBAY FUND MANAGEMENT, LLC | $744K | $14.19 | +$0 | +$744K | -0.4% | $4.25B |
| RENAISSANCE TECHNOLOGIES LLC | $647K | $8.73 | +$287K | +$647K | +1.2% | $63.91B |
| Verdad Advisers, LP | $459K | $10.68 | +$459K | +$459K | +1.5% | $88.8M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $327K | $8.06 | +$85K | +$327K | +2.3% | $1.61T |
| BlackRock, Inc.Passive | $297K | $5.86 | +$0 | +$297K | -0.2% | $5.69T |
| Woodline Partners LP | $294K | $10.68 | +$294K | +$294K | -0.1% | $26.43B |
| CARDIFF PARK ADVISORS, LLC | $233K | $14.19 | +$0 | +$233K | +1.9% | $1.25B |
| ACADIAN ASSET MANAGEMENT LLC | $199K | $5.86 | −$83K | +$199K | -0.5% | $70.48B |
| VANGUARD FIDUCIARY TRUST COPassive | $168K | $10.68 | +$171K | +$168K | — | $395.83B |
| CITADEL ADVISORS LLC | $161K | $10.68 | +$163K | +$161K | -0.4% | $138.22B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
+2.34%
avg per quarter
Holders (ex-self)
+2.44%
excl. this stock
Buyers (this Q)
+0.85%
7 buyers · $0.00B in
Sellers (this Q)
+2.40%
4 sellers · $0.00B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-1.2%
how holders react when this stock falls
On quiet Qs
-6.0%
−10% to +10% baseline
On rallies (+10%+)
+3.5%
how they react when this stock rises
Holders' portfolio flow this Q
-2.8%
outflows — trims may be forced
Sellers' portfolio flow this Q
-7.9%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-8.2%
Holder mid (any stock)
-6.0%
Holder rally (any stock)
-5.8%
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 53.1%
Squadron Capital Management LLC--
Affinity Asset Advisors, LLC--
Ikarian Capital, LLC--
Sofinnova Investments, Inc.--
SILVERARC CAPITAL MANAGEMENT, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Affinity Asset Advisors, LLC242KIkarian Capital, LLC238KSquadron Capital Management LLC265KSofinnova Investments, Inc.223KSILVERARC CAPITAL MANAGEMENT, LLC176KExome Asset Management LLC116KPFIZER INC153KAWM Investment Company, Inc.117KOpaleye Management Inc.141KBOOTHBAY FUND MANAGEMENT, LLC70K
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (1 analysts)$15.0014190.0%
Current Price$6.20
Analyst Ratings
11
Buy: 11Hold: 1Sell: 1Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
27.7%retail-1.1pp
30.7%dark+10.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
NextCure, Inc.: Terminal Cash Burn and Severe Dilution Masked by Reverse Splits
Overall Risk
9/10
Fraud
3/10
Dilution
10/10
Insolvency
10/10
Earnings Overstated
2/10
Hidden Liabilities
4/10
Legal
2/10
Audit Warnings
9/10
Hidden Upside
3/10
Contextually Acceptable
3/10